Chardan Capital Reiterates Buy Rating for Palvella Therapeutics (NASDAQ:PVLA)

Palvella Therapeutics (NASDAQ:PVLA)‘s stock had its “buy” rating reissued by investment analysts at Chardan Capital in a note issued to investors on Thursday,Benzinga reports. They presently have a $110.00 price target on the stock. Chardan Capital’s price objective would indicate a potential upside of 31.39% from the stock’s current price.

Several other analysts have also issued reports on the stock. TD Cowen raised their price target on shares of Palvella Therapeutics from $65.00 to $97.00 and gave the stock a “buy” rating in a research report on Thursday, November 6th. HC Wainwright lifted their target price on Palvella Therapeutics from $95.00 to $190.00 and gave the stock a “buy” rating in a research report on Thursday, November 6th. Raymond James Financial set a $54.00 price target on Palvella Therapeutics and gave the company an “outperform” rating in a research note on Tuesday, August 5th. Stifel Nicolaus raised their price objective on Palvella Therapeutics from $60.00 to $80.00 and gave the stock a “buy” rating in a research report on Wednesday, September 24th. Finally, Truist Financial boosted their price objective on Palvella Therapeutics from $80.00 to $105.00 and gave the company a “buy” rating in a research report on Monday, November 10th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $104.50.

Palvella Therapeutics Stock Up 4.0%

Shares of NASDAQ PVLA opened at $83.72 on Thursday. Palvella Therapeutics has a 12 month low of $11.17 and a 12 month high of $85.03. The company has a market cap of $925.94 million, a P/E ratio of -22.09 and a beta of -0.05. The business’s 50 day moving average is $68.80 and its two-hundred day moving average is $44.66.

Palvella Therapeutics (NASDAQ:PVLA) last announced its quarterly earnings data on Tuesday, November 11th. The company reported ($1.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.18). Sell-side analysts expect that Palvella Therapeutics will post -3.69 earnings per share for the current fiscal year.

Institutional Trading of Palvella Therapeutics

Several institutional investors have recently bought and sold shares of PVLA. Clio Asset Management LLC acquired a new position in Palvella Therapeutics during the second quarter worth $2,063,000. Woodline Partners LP bought a new stake in shares of Palvella Therapeutics in the 1st quarter worth about $5,435,000. Goldman Sachs Group Inc. acquired a new stake in shares of Palvella Therapeutics during the 1st quarter worth about $533,000. Frazier Life Sciences Management L.P. lifted its holdings in Palvella Therapeutics by 5.5% during the 1st quarter. Frazier Life Sciences Management L.P. now owns 690,012 shares of the company’s stock valued at $19,313,000 after purchasing an additional 36,120 shares during the last quarter. Finally, Royce & Associates LP acquired a new position in Palvella Therapeutics in the first quarter valued at about $2,002,000. Institutional investors and hedge funds own 40.11% of the company’s stock.

Palvella Therapeutics Company Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.